MondayOct 16, 2023 11:15 am

Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS

In line with recent emphasis on the growing importance of nanotechnology in the US, Clene Nanomedicine innovated its investigational drug, CNM-Au8(R), using nanotechnology for the treatment of neurodegenerative disease Clene’s nanotechnological approach was recently recognized by the NINDS of NIH with a substantial grant to conduct an Expanded Access Protocol in ALS with CNM-Au8(R) Clene aims to file a New Drug Application for CNM-Au8(R) for ALS indications in the first half of 2024 October 2023 has turned into a month for the celebration of nanotechnology. On Wednesday, Oct. 4, 2023, three U.S.-based scientists, Moungi Bawendi, Louis Brus, and Aleksey Ekimov,…

Continue Reading

FridayOct 13, 2023 12:38 pm

A Deeper Look at the $9.99 Pricing Strategy in eCommerce

Anyone who has browsed through online or physical stores has noticed that retailers have a propensity for slapping price tags that end with .99 on their products. This method has been a common practice in commerce for decades, and according to consumer behavior experts, ending product prices with .99 helps to sell more goods as consumers tend to resonate with the first digit of a price. Consequently, consumers are more likely to purchase a product worth $9.99 over a $10.00 product even though both products essentially cost the same. With e-commerce constantly growing and evolving as millions of retailers fight…

Continue Reading

ThursdayOct 12, 2023 1:46 pm

Researchers Look for Novel Immunomodulating Targets with Potential to Transform Glioblastoma Treatment

Glioblastoma remains one of the most debilitating and difficult-to-treat types of brain cancer. This type of cancer originates from the supportive tissue of nerve cells in the brain and spinal cord before very quickly invading and damaging healthy brain tissue. The speed with which glioblastomas proliferate, their proximity to crucial brain tissue and their potent immune-suppression abilities make treating glioblastomas incredibly difficult and often result in low survival outcomes for patients once they are diagnosed. With a five-year survival rate of only 6.9% and an average postdiagnosis survival rate of around eight months, glioblastoma takes more than 100,000 lives in…

Continue Reading

ThursdayOct 12, 2023 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) CEO Presents ASD Pipeline and Corporate Presentation at H.C. Wainwright 25th Annual Global Investment Conference

Howard Weisman presented PaxMedica’s goals and plans to investors at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 The presentation defined the company’s intention to generate significant funding for its ASD program by first gaining approval for suramin sodium in the treatment of a rare and deadly infection using the same drug The global ASD treatment market was valued at $2.02 billion and is expected to reach $3.28 billion by 2030 Howard Weisman, CEO of PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum…

Continue Reading

WednesdayOct 11, 2023 2:37 pm

Syndromic Testing Could Transform Infectious Disease Diagnosis

The coronavirus pandemic put a spotlight on the potential danger of infectious diseases and has helped spur research to develop faster and more efficient means of diagnosing infectious diseases. Early diagnosis of infectious diseases is critical to developing proper treatment and prevention protocols. It can save a patient’s life and prevent them from spreading the infectious disease to other people while they are still undiagnosed, reducing the likelihood of outbreaks occurring and crippling healthcare systems. With the demand for quick and accurate infectious disease diagnosis rising by the day, researchers are constantly working to develop novel techniques such as syndromic…

Continue Reading

TuesdayOct 10, 2023 3:27 pm

Patients with Metastatic Solid Tumors Have Better Outcomes After Prophylactic Radiation, Study Finds

A new study has revealed that prophylactic radiation may be able to improve treatment outcomes for patients with solid metastatic tumors. Prophylactic cranial radiation (PCR) or prophylactic cranial irradiation (PCI) is a type of radiation therapy used to kill cancer cells from cancers such as small-cell lung cancer that have spread to the brain and prevent further invasion of brain tissue. According to a paper published in the “Journal of Clinical Oncology,” applying prophylactic radiation to asymptomatic bone metastases in patients diagnosed with solid tumor malignancies can improve patient outcomes. During phase 2 trials, patients who received prophylactic radiation reported…

Continue Reading

MondayOct 09, 2023 10:28 am

Five Must-Have Design Features for e-Commerce Sites

With a share of close to 19% of total retail sales, e-commerce plays an increasingly large role in the American retail market. Millions of online stores are fighting to attract customers, and around 80% to 90% of them fail before they can build a market presence. Although this extremely high failure rate is caused by factors such as poor marketing, limited search visibility and intense competition, poor design can also lower your website’s chances of success. To stand out from the more than 26.5 million e-commerce websites fighting to succeed in the online sales segment, you will have to implement…

Continue Reading

FridayOct 06, 2023 11:52 am

First Time Ever: Researchers Eliminate Brain Cancer Using Quantum Therapy

University of Nottingham scientists have developed a new quantum therapeutic approach to treating cancer that could treat one of the most aggressive types of brain cancer, glioblastoma. The researchers created a new spray treatment capable of treating glioblastoma through quantum signaling, making their treatment the first-ever, quantum-therapy-based treatment. This unique treatment works by changing neural cells at a quantum level via bio-nanoantennas, nano-particles of gold coated in redox-active molecules. According to the researchers, the novel treatment involves spraying glioblastoma tumor sites with bio-nanoantennae followed by the application of an electric field. University of Nottingham research fellow and study coauthor Frannkie…

Continue Reading

ThursdayOct 05, 2023 12:38 pm

Researchers Find Psoriasis Increases Risk of Heart Disease

Researchers have observed coronary microvascular dysfunction in a good number of patients with psoriasis. This is despite the fact that most of them hadn’t presented with any symptoms of cardiovascular illness. For their study, the researchers recruited 503 individuals who had been diagnosed with psoriasis but had not been diagnosed with cardiovascular disease. Prior research has demonstrated that individuals with severe psoriasis have heightened cardiovascular mortality and morbidity. Despite this, there’s been limited studies on the mechanisms underlying the heightened risk. The researchers were focused on learning more about the link between psoriasis and heart disease, centering on coronary blood…

Continue Reading

WednesdayOct 04, 2023 3:32 pm

New Prediction Model Could Slash Unnecessary Pancreatic Cancer Biopsies

Researchers have developed a new prediction model capable of “reliably detecting” pancreatic cancer in its early stages. The prediction model leverages regularly measured biomarkers in the blood to sharpen diagnostic processes for pancreatic cancer and reduce the need for unnecessary biopsy procedures by 6%. Pancreatic cancer is difficult to diagnose in its early stages because the pancreas is generally hidden by other organs and is located deep in the abdomen. Furthermore, pancreatic cancer often displays no physical symptoms until the cancer has metastasized to other organs, which makes the condition easy to miss during physical exams or through analyzing symptoms.…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000